FLT3 and acute myeloid leukemia: Patients who are older than 60 years have even poorer prognoses (5-year survival rates <10%).[1] In recent years, inhibitors of FMS-like tyrosine kinase 3 (FLT3) have emerged as promising treatment options for AML.